Rapid tumor regression in an Asian lung cancer patient following personalized neo-epitope peptide vaccination

OncoImmunology

Volumn 5, Issue 12, 2016, Pages

  Li, Fenge ^a,b   Chen, Caixia ^c   Ju, Tao ^c   Gao, Junqin ^c   Yan, Jun ^a   Wang, Peng ^d   Xu, Qiang ^e   Hwu, Patrick ^f   Du, Xueming ^c   Lizée, Gregory ^f  

^a TIANJIN FIRST CENTRAL HOSPITAL   (China)

^b Tianjin HengJia Biotechnology Development Co Ltd   (China)

^c Beichen Hospital   (China)

^d Third Central Hospital   (China)

^e GenomiCare Biotechnology Co Ltd Ltd   (China)

^f UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Cancer vaccine; cytotoxic T cells; EGFR L858R mutation; epidermal growth factor receptor; lung cancer; neo epitope; personalized immunotherapy

Indexed keywords

EPHRIN RECEPTOR B1; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; GAMMA INTERFERON; IMIQUIMOD; NAVELBINE; NEURON NAVIGATOR 3; PEPTIDE; PROTEIN KINASE LKB1; PROTEIN PATCHED 2; UNCLASSIFIED DRUG;

AGED; ARTICLE; ASIAN; CANCER STAGING; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; COUGHING; DISEASE COURSE; DYSPNEA; ENZYME LINKED IMMUNOSORBENT ASSAY; FEVER; GENE MUTATION; HLA TYPING; HUMAN; LUNG CANCER; MALE; MULTIPLE CYCLE TREATMENT; NEXT GENERATION SEQUENCING; THORAX PAIN; TUMOR REGRESSION; VACCINATION; VERY ELDERLY;

EID: 84996848680     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.1080/2162402X.2016.1238539     Document Type: Article

References (40)

1. Hecht SS. Lung carcinogenesis by tobacco smoke. Int J Cancer 2012; 131(12):2724-32; PMID:22945513; http://dx.doi.org/10.1002/ijc.27816
2. Lawrence MS, Stojanov P, Polak P, Kryukov GV, Cibulskis K, Sivachenko A, Carter SL, Stewart C, Mermel CH, Roberts SA, et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature 2013; 499(7457):214-8; PMID:23770567; http://dx.doi.org/10.1038/nature12213
3. Rizvi NA, Hellmann MD, Snyder A, Kvistborg P, Makarov V, Havel JJ, Lee W, Yuan J, Wong P, Ho TS, et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 2015; 348(6230):124-8; PMID:25765070; http://dx.doi.org/10.1126/science.aaa1348
4. McGranahan N, Furness AJ, Rosenthal R, Ramskov S, Lyngaa R, Saini SK, Jamal-Hanjani M, Wilson GA, Birkbak NJ, Hiley CT, et al. Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade. Science 2016; 351(6280):1463-9; PMID:26940869; http://dx.doi.org/10.1126/science.aaf1490
5. Van Allen EM, Miao D, Schilling B, Shukla SA, Blank C, Zimmer L, Sucker A, Hillen U, Geukes Foppen MH, Goldinger SM, et al. Genomic correlates of response to CTLA-4 blockade in metastatic melanoma. Science 2015; 350(6257):207-11; PMID:26359337; http://dx.doi.org/10.1126/science.aad0095
6. Schumacher TN, Schreiber RD. Neoantigens in cancer immunotherapy. Science 2015; 348(6230):69-74; PMID:25838375; http://dx.doi.org/10.1126/science.aaa4971
7. Gubin MM, Zhang X, Schuster H, Caron E, Ward JP, Noguchi T, Ivanova Y, Hundal J, Arthur CD, Krebber WJ, et al. Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens. Nature 2014; 515(7528):577-81; PMID:25428507; http://dx.doi.org/10.1038/nature13988
8. Coulie PG, Van den Eynde BJ, van der Bruggen P, Boon T. Tumour antigens recognized by T lymphocytes:at the core of cancer immunotherapy. Nat Rev Cancer 2014; 14(2):135-46; PMID:24457417; http://dx.doi.org/10.1038/nrc3670
9. Gubin MM, Artyomov MN, Mardis ER, Schreiber RD. Tumor neoantigens:building a framework for personalized cancer immunotherapy. J Clin Invest 2015; 125(9):3413-21; PMID:26258412; http://dx.doi.org/10.1172/JCI80008
10. Robbins PF, Lu YC, El-Gamil M, Li YF, Gross C, Gartner J, Lin JC, Teer JK, Cliften P, Tycksen E, et al. Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells. Nat Med 2013; 19(6):747-52; PMID:23644516; http://dx.doi.org/10.1038/nm.3161
11. Della Vittoria Scarpati G, Fusciello C, Perri F, Sabbatino F, Ferrone S, Carlomagno C, Pepe S. Ipilimumab in the treatment of metastatic melanoma:management of adverse events. Onco Targets Ther 2014; 7:203-9; PMID:24570590; http://dx.doi.org/10.2147/OTT.S57335
12. Haanen JB, Thienen HV, Blank CU. Toxicity patterns with immunomodulating antibodies and their combinations. Semin Oncol 2015; 42(3):423-8; PMID:25965360; http://dx.doi.org/10.1053/j.seminoncol.2015.02.011
13. Carreno BM, Magrini V, Becker-Hapak M, Kaabinejadian S, Hundal J, Petti AA, Ly A, Lie WR, Hildebrand WH, Mardis ER, et al. Cancer immunotherapy. A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells. Science 2015; 348(6236):803-8; PMID:25837513; http://dx.doi.org/10.1126/science.aaa3828
14. Kreiter S, Vormehr M, van de Roemer N, Diken M, Löwer M, Diekmann J, Boegel S, Schrörs B, Vascotto F, Castle JC, et al. Mutant MHC class II epitopes drive therapeutic immune responses to cancer. Nature 2015; 520(7549):692-6; PMID:25901682; http://dx.doi.org/10.1038/nature14426
15. van der Burg SH, Arens R, Ossendorp F, van Hall T, Melief CJ. Vaccines for established cancer:overcoming the challenges posed by immune evasion. Nat Rev Cancer 2016; 16(4):219-33; PMID:26965076; http://dx.doi.org/10.1038/nrc.2016.16
16. Pol J, Bloy N, Buqué A, Eggermont A, Cremer I, Sautès-Fridman C, Galon J, Tartour E, Zitvogel L, Kroemer G, et al. Trial Watch:Peptide-based anticancer vaccines. Oncoimmunology 2015; 4(4):e974411; PMID:26137405; http://dx.doi.org/10.4161/2162402X.2014.974411
17. Lundegaard C, Lund O, Nielsen M. Prediction of epitopes using neural network based methods. J Immunol Methods 2011; 374(1–2):26-34; PMID:21047511; http://dx.doi.org/10.1016/j.jim.2010.10.011
18. Nielsen M, Lund O. NN-align. An artificial neural network-based alignment algorithm for MHC class II peptide binding prediction. BMC Bioinformatics 2009; 10:296; PMID:19765293; http://dx.doi.org/10.1186/1471-2105-10-296
19. Nestle FO, Alijagic S, Gilliet M, Sun Y, Grabbe S, Dummer R, Burg G, Schadendorf D. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med 1998; 4(3):328-32; PMID:9500607; http://dx.doi.org/10.1038/nm0398-328
20. Schwartzentruber DJ, Lawson DH, Richards JM, Conry RM, Miller DM, Treisman J, Gailani F, Riley L, Conlon K, Pockaj B, et al. gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma. N Engl J Med 2011; 364(22):2119-27; PMID:21631324; http://dx.doi.org/10.1056/NEJMoa1012863
21. Slingluff CL, Jr, Petroni GR, Chianese-Bullock KA, Smolkin ME, Ross MI, Haas NB, von Mehren M, Grosh WW. Randomized multicenter trial of the effects of melanoma-associated helper peptides and cyclophosphamide on the immunogenicity of a multipeptide melanoma vaccine. J Clin Oncol 2011; 29(21):2924-32; PMID:21690475; http://dx.doi.org/10.1200/JCO.2010.33.8053
22. van Poelgeest MI, Welters MJ, van Esch EM, Stynenbosch LF, Kerpershoek G, van Persijn van Meerten EL, van den Hende M, Löwik MJ, Berends-van der Meer DM, Fathers LM, et al. HPV16 synthetic long peptide (HPV16-SLP) vaccination therapy of patients with advanced or recurrent HPV16-induced gynecological carcinoma, a phase II trial. J Transl Med 2013; 11:88; PMID:23557172; http://dx.doi.org/10.1186/1479-5876-11-88
23. Bernatchez C, Cooper ZA, Wargo JA, Hwu P, Lizée G. Novel treatments in development for Melanoma. Cancer Treat Res 2016; 167:371-416; PMID:26601872; http://dx.doi.org/10.1007/978-3-319-22539-5_16
24. Lu YC, Robbin PF. Cancer immunotherapy targeting neoantigens. Semin Immunol 2016; 28(1):22-7; PMID:26653770; http://dx.doi.org/10.1016/j.smim.2015.11.002
25. Tran E, Turcotte S, Gros A, Robbins PF, Lu YC, Dudley ME, Wunderlich JR, Somerville RP, Hogan K, Hinrichs CS, et al. Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer. Science 2014; 344(6184):641-5; PMID:24812403; http://dx.doi.org/10.1126/science.1251102
26. Tran E, Ahmadzadeh M, Lu YC, Gros A, Turcotte S, Robbins PF, Gartner JJ, Zheng Z, Li YF, Ray S, et al. Immunogenicity of somatic mutations in human gastrointestinal cancers. Science 2015; 350(6266):1387-90; PMID:26516200; http://dx.doi.org/10.1126/science.aad1253
27. Linnemann C, van Buuren MM, Bies L, Verdegaal EM, Schotte R, Calis JJ, Behjati S, Velds A, Hilkmann H, Atmioui DE, et al. High-throughput epitope discovery reveals frequent recognition of neo-antigens by CD4+ T cells in human melanoma. Nat Med 2015; 21(1):81-5; PMID:25531942; http://dx.doi.org/10.1038/nm.3773
28. Trajanoski Z, Maccalli C, Mennonna D, Casorati G, Parmiani G, Dellabona P. Somatically mutated tumor antigens in the quest for a more efficacious patient-oriented immunotherapy of cancer. Cancer Immunol Immunother 2015; 64(1):99-104; PMID:25164877; http://dx.doi.org/10.1007/s00262-014-1599-7
29. Lizée G, Overwijk WW, Radvanyi L, Gao J, Sharma P, Hwu P. Harnessing the power of the immune system to target cancer. Annu Rev Med 2013; 64:71-90; PMID:23092383; http://dx.doi.org/10.1146/annurev-med-112311-083918
30. Hailemichael Y, Dai Z, Jaffarzad N, Ye Y, Medina MA, Huang XF, Dorta-Estremera SM, Greeley NR, Nitti G, Peng W, et al. Persistent antigen at vaccination sites induces tumor-specific CD8+ T cell sequestration, dysfunction and deletion. Nat Med 2013; 19(4):465-72; PMID:23455713; http://dx.doi.org/10.1038/nm.3105
31. Tan DS, Yom SS, Tsao MS, Pass HI, Kelly K, Peled N, Yung RC, Wistuba II, Yatabe Y, Unger M, et al. The international association for the study of lung cancer consensus statement on optimizing management of EGFR mutation positive non-small cell lung cancer:status in 2016. J Thorac Oncol 2016; 11(7):946-63 May 20; pii:S1556-0864(16)30458-0; PMID:27229180; http://dx.doi.org/10.1016/j.jtho.2016.05.008
32. González-Galarza FF, Takeshita LY, Santos EJ, Kempson F, Maia MH, da Silva AL, Teles e Silva AL, Ghattaoraya GS, Alfirevic A, Jones AR, et al. Allele frequency net 2015 update:new features for HLA epitopes, KIR and disease and HLA adverse drug reaction associations. Nucleic Acids Res 2015; 43:D784-8; PMID:25414323; http://dx.doi.org/10.1093/nar/gku1166
33. Kroemer G, Zitvogel L. Can the exome and the immunome converge on the design of efficient cancer vaccines? Oncoimmunology 2012; 1(5):579-580; PMID:22934249; http://dx.doi.org/10.4161/onci.20730
34. Heemskerk B, Kvistborg P, Schumacher TN. The cancer antigenome. EMBO J 2013; 32(2):194-203; PMID:23258224; http://dx.doi.org/10.1038/emboj.2012.333
35. Yadav M, Jhunjhunwala S, Phung QT, Lupardus P, Tanguay J, Bumbaca S, Franci C, Cheung TK, Fritsche J, Weinschenk T, et al. Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing. Nature 2014; 515(7528):572-6; PMID:25428506; http://dx.doi.org/10.1038/nature14001
36. Bassani-Sternberg M, Coukos G. Mass spectrometry-based antigen discovery for cancer immunotherapy. Curr Opin Immunol 2016; 41:9-17; PMID:27155075; http://dx.doi.org/10.1016/j.coi.2016.04.005
37. Martin SD, Brown SD, Wick DA, Nielsen JS, Kroeger DR, Twumasi-Boateng K, Holt RA, Nelson BH. Low mutation burden in ovarian cancer may limit the utility of neoantigen-targeted vaccines. PLoS One 2016; 11(5):e0155189; PMID:27192170; http://dx.doi.org/10.1371/journal.pone.0155189
38. de Bruin EC, McGranahan N, Mitter R, Salm M, Wedge DC, Yates L, Jamal-Hanjani M, Shafi S, Murugaesu N, Rowan AJ, et al. Spatial and temporal diversity in genomic instability processes defines lung cancer evolution. Science 2014; 346(6206):251-6; PMID:25301630; http://dx.doi.org/10.1126/science.1253462
39. Heymann F, Tacke F. Immunology in the liver - from homeostasis to disease. Nat Rev Gastroenterol Hepatol 2016; 13(2):88-110; PMID:26758786; http://dx.doi.org/10.1038/nrgastro.2015.200
40. Zahreddine H, Borden KL. Mechanisms and insights into drug resistance in cancer. Front Pharmacol 2013; 4:28; PMID:23504227; http://dx.doi.org/10.3389/fphar.2013.00028